Recursion Pharmaceuticals Inc RXRX shares are under pressure Wednesday after new regulatory filings showed that Nvidia Corp NVDA has fully exited its investment in the AI‑focused drug‑discovery ...
Zacks Investment Research on MSN
Recursion Pharmaceuticals to report Q4 earnings: What's in the cards?
Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...
Nvidia sold its position in Recursion Pharmaceuticals, while others keep a measured outlook. Does this divergence signal risk ...
Recursion will host a (L)earnings Call on February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion’s X, LinkedIn, and YouTube accounts.
If you are trying to figure out whether Recursion Pharmaceuticals is attractively priced or a high risk speculation, a useful ...
Don't call Recursion Pharmaceuticals (NASDAQ: RXRX) a biotech company. Its management prefers the term "TechBio." While many have been skeptical about TechBio in the past, the reception is changing ...
Nvidia sold its entire 7.71M share stake as ARK Invest bought 1.25M shares; RXRX swung 14% before closing 2% higher Wednesday.
Chris Gibson, PhD, Recursion’s co-founder and CEO, discusses exclusively with GEN Edge his company’s ambitious plans to develop 100 pipeline candidates in roughly a decade, the savings in money and ...
The concept of a meme stock was born about five years ago. It refers to a publicly traded company that gains substantial market value practically overnight (sometimes literally) due to significant ...
Cathie Wood's ARK Invest bought Recursion Pharmaceuticals and CRISPR Therapeutics while selling PagerDuty, Teradyne, and Salesforce on8, 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results